These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 26611431)

  • 21. Multiple sclerosis patients with anti-lipid oligoclonal IgM show early favourable response to immunomodulatory treatment.
    García-Barragán N; Villar LM; Espiño M; Sádaba MC; González-Porqué P; Alvarez-Cermeño JC
    Eur J Neurol; 2009 Mar; 16(3):380-5. PubMed ID: 19175382
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New therapeutic approaches for multiple sclerosis.
    De Jager PL; Hafler DA
    Annu Rev Med; 2007; 58():417-32. PubMed ID: 17217332
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New options for early treatment of multiple sclerosis.
    Tintoré M
    J Neurol Sci; 2009 Feb; 277 Suppl 1():S9-S11. PubMed ID: 19200870
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Natural history of multiple sclerosis: a unifying concept.
    Confavreux C; Vukusic S
    Brain; 2006 Mar; 129(Pt 3):606-16. PubMed ID: 16415308
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunologic aspects of multiple sclerosis.
    Boppana S; Huang H; Ito K; Dhib-Jalbut S
    Mt Sinai J Med; 2011; 78(2):207-20. PubMed ID: 21425265
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A changing treatment landscape for multiple sclerosis: challenges and opportunities.
    Piehl F
    J Intern Med; 2014 Apr; 275(4):364-81. PubMed ID: 24444084
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Immunotherapies for multiple sclerosis : review and update].
    Havla J; Kümpfel T; Hohlfeld R
    Internist (Berl); 2015 Apr; 56(4):432-45. PubMed ID: 25720530
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment options for multiple sclerosis: current and emerging therapies.
    Gawronski KM; Rainka MM; Patel MJ; Gengo FM
    Pharmacotherapy; 2010 Sep; 30(9):916-27. PubMed ID: 20795847
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Current state of research on multiple sclerosis].
    Lubina-Dabrowska N; Stepień A; Chalimoniuk M
    Pol Merkur Lekarski; 2013 Mar; 34(201):135-9. PubMed ID: 23700821
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).
    Jacobs LD; Cookfair DL; Rudick RA; Herndon RM; Richert JR; Salazar AM; Fischer JS; Goodkin DE; Granger CV; Simon JH; Alam JJ; Bartoszak DM; Bourdette DN; Braiman J; Brownscheidle CM; Coats ME; Cohan SL; Dougherty DS; Kinkel RP; Mass MK; Munschauer FE; Priore RL; Pullicino PM; Scherokman BJ; Whitham RH
    Ann Neurol; 1996 Mar; 39(3):285-94. PubMed ID: 8602746
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relapses and progression of disability in multiple sclerosis.
    Confavreux C; Vukusic S; Moreau T; Adeleine P
    N Engl J Med; 2000 Nov; 343(20):1430-8. PubMed ID: 11078767
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The challenges of measuring disability accumulation in relapsing-remitting multiple sclerosis: evidence from interferon beta treatments.
    Kieseier BC
    Expert Rev Neurother; 2014 Jan; 14(1):105-20. PubMed ID: 24417500
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term follow-up of clinical trials of multiple sclerosis therapies.
    Freedman MS
    Neurology; 2011 Jan; 76(1 Suppl 1):S26-34. PubMed ID: 21205679
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis.
    Sørensen PS
    J Neurol Sci; 2011 Dec; 311 Suppl 1():S29-34. PubMed ID: 22206763
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Current treatment of multiple sclerosis].
    Gout O; Bensa C; Assouad R
    Rev Med Interne; 2010 Aug; 31(8):575-80. PubMed ID: 20579785
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The influence of immunomodulatory treatment on the clinical course of multiple sclerosis.
    Kavaliunas A; Stawiarz L; Hedbom J; Glaser A; Hillert J
    Adv Exp Med Biol; 2015; 822():19-24. PubMed ID: 25416973
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacologic management of multiple sclerosis.
    Blasier MG
    Urol Nurs; 2008 Jun; 28(3):217-9. PubMed ID: 18605517
    [No Abstract]   [Full Text] [Related]  

  • 38. Optimizing therapy early in multiple sclerosis: An evidence-based view.
    Ziemssen T; De Stefano N; Sormani MP; Van Wijmeersch B; Wiendl H; Kieseier BC
    Mult Scler Relat Disord; 2015 Sep; 4(5):460-469. PubMed ID: 26346796
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modern multiple sclerosis treatment - what is approved, what is on the horizon.
    Pilz G; Wipfler P; Ladurner G; Kraus J
    Drug Discov Today; 2008 Dec; 13(23-24):1013-25. PubMed ID: 18775508
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multiple sclerosis: interferon beta for some serious forms.
    Prescrire Int; 2007 Dec; 16(92):252-7. PubMed ID: 18092425
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.